Clozapine Neutropenia Risk Results in FDA Warning Update
Amid concerns about the potential side effects of clozapine, federal health officials are requiring new warnings and patient monitoring for the schizophrenia medicine, indicating that there is growing evidence that users may face an increased risk of a severe blood condition, known as neutropenia.
In a drug safety communication issued September 15, the FDA announced changes to the requirements for monitoring, prescribing, dispensing, and receiving of the schizophrenia medicine clozapine, which is available generically and sold under the brand names Clozaril and FazaClo.
Clozapine is an antipsychotic medication used to treat patients diagnosed with severe schizophrenia whose symptoms cannot be controlled by standard antipsychotic treatment or therapies. The medication has also been used to treat reoccurring suicidal behavior in patients with schizophrenia or schizoaffective disorder. The drug is used to block various receptors in the brain and restore balance in patient’s dopamine and serotonin level.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
The new clozapine warnings come amid a growing trend of patients experiencing severe neutropenia, a serious blood condition that causes dangerously low white blood cell counts. As a result of the low white blood cell count, patients are very susceptible to infections. The condition is extremely harmful and can be life threatening, especially in the elderly and those with weakened immune systems.
Due to the clozapine neutropenia side effects, the FDA is requiring clarified and enhanced prescribing information that explains how to monitor patients for the blood condition and how to manage patients treatments. Secondly, the FDA has passed a new shared risk evaluation and mitigation strategy (REMS), called the Clozapine REMS Program, which is expected to reduce the burden and possible confusion related to having separate registries for individual clozapine medicines.
The new requirements will mandate prescribing doctors to perform an absolute neutrophil count (ANC) that will continuously be performed and evaluated to ensure the patient’s white blood cells do not reach dangerous levels. The REMS Program requires that for outpatients the ANC test results be reported before the Clozapine prescription is dispensed and for inpatients the ANC test results must be reported within 7 days of the most recent blood sample. Additional provisions will require all prescribers and pharmacies to be certified in the Clozapine REMS Program following a specific transition starting on October 12, 2015.
LindaJanuary 8, 2020 at 7:19 pm
Being courted ordered forced to take clonopin and colziril against my will
Mary LynnOctober 11, 2019 at 9:33 pm
This is all fine and dandy but my son got cardiomyopathy and died from this drug due to his heart functioning at 10% when he was admitted into ICU. When oh when is this going to get out there? I just cannot believe that it has not been disclosed yet. Mary Ludwig * in memory of my son Bradley Collins who died at 26 years old
"*" indicates required fields
More Top Stories
The U.S. JPML has consolidated all Tepezza lawsuits over hearing loss before one Northern Illinois federal judge for coordinated pretrial proceedings.
Bard claims two cases selected for the third and fourth bellwether trials are no longer representative of the litigation due to the plaintiffs' worsening injuries and need for additional surgeries due to their failed hernia mesh products.
More than 775 Exactech lawsuits have been filed in federal and state courts as parties work toward a plan for bellwether early test trials.